
SWPIF
Healthcare · Drug Manufacturers - Specialty & Generic · $2.11B market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 11, 2021 | Time not confirmed | -111.61 | -115.31 | -3.3% |
| Feb 11, 2021 | Time not confirmed | 171.30 | 150.46 | -12.2% |
| Dec 31, 2020 | Time not confirmed | 108.78 | 1.46 | -98.7% |
| Sep 30, 2020 | Time not confirmed | 117.80 | 1.15 | -99.0% |
| Jun 30, 2020 | Time not confirmed | 72.69 | 1.16 | -98.4% |
| Mar 31, 2020 | Time not confirmed | 143.91 | 0.42 | -99.7% |
| Dec 31, 2019 | Time not confirmed | 140.80 | 1.33 | -99.1% |
| Sep 30, 2019 | Time not confirmed | 121.07 | 0.96 | -99.2% |
| Jun 30, 2019 | Time not confirmed | 43.35 | 1.36 | -96.9% |
| Mar 31, 2019 | Time not confirmed | 114.23 | 0.53 | -99.5% |
| Dec 31, 2018 | Time not confirmed | 76.36 | 1.31 | -98.3% |
| Sep 30, 2018 | Time not confirmed | 86.82 | 1.06 | -98.8% |
| Jun 30, 2018 | Time not confirmed |
Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research, development, manufacturing, and marketing of generic pharmaceutical products primarily in Japan and the United States. It offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms in the therapeutic areas…
| -29.79 |
| 1.08 |
| +103.6% |
| Mar 31, 2018 | Time not confirmed | 110.42 | -0.01 | -100.0% |